Abstract
We aimed to evaluate the correlation between two methods of the detection of antibody to hepatitis B core antigen (anti-HBc); chemiluminescent immunoassay (CLIA; Architect®Anti-HBc II) and passive hemagglutination assay (PHA; Mycell®anti-rHBc). 249 positive cases and 436 negative cases among 685 employees were determined. The percent agreement between CLIA and PHA was 96.4%. Positive values by PHA were distributed from 26 to 222 fold, while those of CLIA from 1.0 to 26.6 S/CO. High titers more than 10 S/CO by CLIA were equivalent to over 210 fold by PHA. While in low titers of anti-HBc PHA was slightly lower in sensitivity than CLIA, PHA is more quantitative than CLIA in high titers of anti-HBc.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
